{"id":2391,"date":"2017-11-06T18:12:15","date_gmt":"2017-11-06T12:42:15","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2391"},"modified":"2025-05-12T14:37:33","modified_gmt":"2025-05-12T09:07:33","slug":"wiskott-aldrich-syndrome-rare-x-linked-disorder","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/wiskott-aldrich-syndrome-rare-x-linked-disorder","title":{"rendered":"Wiskott &#8211; Aldrich syndrome \u2013 a rare X-linked disorder"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Wiskott &#8211; Aldrich syndrome (also known as WAS)<\/strong> is a rare X-linked recessive genetic disorder that affects both T-lymphocytes and B-lymphocytes. It occurs due to the mutations caused in the WASp gene and is mainly characterized by low platelet count (microthrombocytopenia), immune deficiency, and eczema.<\/p>\n<p style=\"text-align: justify;\">Being an <strong>X-linked disorder<\/strong>, it occurs almost exclusively in the male population with an incidence of 4 in 1 million live births in the United States. A similar incidence is observed ex-US.<strong> The incidence data from the 7MM including US, UK, Germany, Spain, Italy, France and Japan in 2015 showed that there were only 33 incident cases of WAS<\/strong>. The presentation of the disease is mostly reported in the first two years of life. In terms of prevalence, US had the maximum reported prevalent cases of 500 in 2015, while Spain had the lowest prevalent cases (57) reported amongst the seven major markets in 2015.<\/p>\n<p style=\"text-align: justify;\">Currently, the therapeutic market of WAS only comprises of symptomatic treatments for primary immunodeficiency, thrombocytopenia and eczema with no commercially available curative drugs. The additional treatment strategy used is the hematopoietic stem cell transplantation but the unavailability of direct-acting therapies becomes a high unmet need. The current therapeutic research and development constitutes three major players including <strong>GlaxoSmithKline (Phase III), Genethon (Phase II) and Bellicum Pharmaceuticals (Phase II).<\/strong><\/p>\n<p style=\"text-align: justify;\">It is expected that these upcoming curative products will <strong>have a high market and patient acceptance post-launch.<\/strong><\/p>\n<p><strong>Insights by:<br \/>\n<\/strong><strong><em>Ayushi Sinha<br \/>\n<\/em><\/strong><strong><em>Associate Analyst<\/em><\/strong><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wiskott &#8211; Aldrich syndrome (also known as WAS) is a rare X-linked recessive genetic disorder that affects both T-lymphocytes and B-lymphocytes. It occurs due to the mutations caused in the WASp gene and is mainly characterized by low platelet count (microthrombocytopenia), immune deficiency, and eczema. Being an X-linked disorder, it occurs almost exclusively in the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2393,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[17589,1128,17588,985,440,502,1123,1127,1124,1126,1125,17590],"industry":[17225],"therapeutic_areas":[17238,17234],"class_list":["post-2391","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-bellicum-pharmaceuticals","tag-forecasted-market-size-2015-2025","tag-genethon","tag-glaxosmithkline","tag-orphan-disease","tag-rare-disease","tag-wiskott-aldrich-syndrome","tag-wiskott-aldrich-syndrome-companies","tag-wiskott-aldrich-syndrome-market","tag-wiskott-aldrich-syndrome-market-size","tag-wiskott-aldrich-syndrome-pipeline","tag-x-linked-disorder","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Wiskott - Aldrich syndrome \u2013 a rare X-linked disorder - DELVEINSIGHT<\/title>\n<meta name=\"description\" content=\"Wiskott - Aldrich syndrome (also known as WAS) is a rare X-linked recessive genetic disorder that affects both T-lymphocytes and B-lymphocytes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/wiskott-aldrich-syndrome-rare-x-linked-disorder\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wiskott - Aldrich syndrome \u2013 a rare X-linked disorder - DELVEINSIGHT\" \/>\n<meta property=\"og:description\" content=\"Wiskott - Aldrich syndrome (also known as WAS) is a rare X-linked recessive genetic disorder that affects both T-lymphocytes and B-lymphocytes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/wiskott-aldrich-syndrome-rare-x-linked-disorder\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-11-06T12:42:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T09:07:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/10223207\/Presentation1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Wiskott - Aldrich syndrome \u2013 a rare X-linked disorder - DELVEINSIGHT","description":"Wiskott - Aldrich syndrome (also known as WAS) is a rare X-linked recessive genetic disorder that affects both T-lymphocytes and B-lymphocytes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/wiskott-aldrich-syndrome-rare-x-linked-disorder","og_locale":"en_US","og_type":"article","og_title":"Wiskott - Aldrich syndrome \u2013 a rare X-linked disorder - DELVEINSIGHT","og_description":"Wiskott - Aldrich syndrome (also known as WAS) is a rare X-linked recessive genetic disorder that affects both T-lymphocytes and B-lymphocytes.","og_url":"https:\/\/www.delveinsight.com\/blog\/wiskott-aldrich-syndrome-rare-x-linked-disorder","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-11-06T12:42:15+00:00","article_modified_time":"2025-05-12T09:07:33+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/10223207\/Presentation1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/wiskott-aldrich-syndrome-rare-x-linked-disorder","url":"https:\/\/www.delveinsight.com\/blog\/wiskott-aldrich-syndrome-rare-x-linked-disorder","name":"Wiskott - Aldrich syndrome \u2013 a rare X-linked disorder - DELVEINSIGHT","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/wiskott-aldrich-syndrome-rare-x-linked-disorder#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/wiskott-aldrich-syndrome-rare-x-linked-disorder#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/10223207\/Presentation1.jpg","datePublished":"2017-11-06T12:42:15+00:00","dateModified":"2025-05-12T09:07:33+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Wiskott - Aldrich syndrome (also known as WAS) is a rare X-linked recessive genetic disorder that affects both T-lymphocytes and B-lymphocytes.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/wiskott-aldrich-syndrome-rare-x-linked-disorder"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/wiskott-aldrich-syndrome-rare-x-linked-disorder#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/10223207\/Presentation1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/10223207\/Presentation1.jpg","width":1280,"height":720,"caption":"WAS"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/10223207\/Presentation1-300x169.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Bellicum Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Forecasted Market Size 2015-2025<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Genethon<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">GlaxoSmithKline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">orphan disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Rare Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Wiskott - Aldrich syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Wiskott - Aldrich syndrome companies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Wiskott - Aldrich syndrome market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Wiskott - Aldrich syndrome market size<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Wiskott - Aldrich syndrome pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">X Linked Disorder<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Bellicum Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Forecasted Market Size 2015-2025<\/span>","<span class=\"advgb-post-tax-term\">Genethon<\/span>","<span class=\"advgb-post-tax-term\">GlaxoSmithKline<\/span>","<span class=\"advgb-post-tax-term\">orphan disease<\/span>","<span class=\"advgb-post-tax-term\">Rare Disease<\/span>","<span class=\"advgb-post-tax-term\">Wiskott - Aldrich syndrome<\/span>","<span class=\"advgb-post-tax-term\">Wiskott - Aldrich syndrome companies<\/span>","<span class=\"advgb-post-tax-term\">Wiskott - Aldrich syndrome market<\/span>","<span class=\"advgb-post-tax-term\">Wiskott - Aldrich syndrome market size<\/span>","<span class=\"advgb-post-tax-term\">Wiskott - Aldrich syndrome pipeline<\/span>","<span class=\"advgb-post-tax-term\">X Linked Disorder<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Nov 6, 2017","modified":"Updated on May 12, 2025"},"absolute_dates_time":{"created":"Posted on Nov 6, 2017 6:12 pm","modified":"Updated on May 12, 2025 2:37 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2391"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2391\/revisions"}],"predecessor-version":[{"id":32058,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2391\/revisions\/32058"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2393"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2391"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2391"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}